Benefits and safety of long-acting calcium antagonists in coronary artery disease: the Action Trial

Affiliations

¹ Hypertension and Cardiovascular Rehabilitation Unit, Department of Molecular and Cardiovascular Research, Faculty of Medicine, University of Leuven KU Leuven, Leuven, Belgium. robert.fagard@uz.kuleuven.ac.be

Editorial

Robert H Fagard. J Hypertens. 2005 Mar.

. 2005 Mar;23(3):489-91.

doi: 10.1097/01.hjh.0000160202.35910.d6.

¹ Hypertension and Cardiovascular Rehabilitation Unit, Department of Molecular and Cardiovascular Research, Faculty of Medicine, University of Leuven KU Leuven, Leuven, Belgium. robert.fagard@uz.kuleuven.ac.be

No abstract available

Comment on

Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial.
Lubsen J, Wagener G, Kirwan BA, de Brouwer S, Poole-Wilson PA; ACTION (A Coronary disease Trial Investigating Outcome with Nifedipine GITS) investigators. Lubsen J, et al. J Hypertens. 2005 Mar;23(3):641-8. doi: 10.1097/01.hjh.0000160223.94220.29. J Hypertens. 2005. PMID: 15716708 Clinical Trial.